Proton beam therapy for patients with medically inoperable stage I non-small-cell lung cancer at the university of tsukuba.

PURPOSE To evaluate in a retrospective review the role of proton beam therapy for patients with medically inoperable Stage I non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS From November 2001 to July 2008, 55 medically inoperable patients with Stage I NSCLC were treated with proton beam therapy. A total of 58 (T1/T2, 30/28) tumors were treated. The median age of study participants was 77 years (range, 52-86 years). A total dose of 66 GyE in 10 fractions was given to peripherally located tumors and 72.6 GyE in 22 fractions to centrally located tumors. RESULTS The rates (95% confidence interval) of overall and progression-free survival of all patients and of local control of all tumors at 2 years were 97.8% (93.6-102.0%), 88.7% (77.9-99.5%), and 97.0% (91.1-102.8%), respectively. There was no statistically significant difference in progression-free rate between T1 and T2 tumors (p = 0.87). Two patients (3.6%) had deterioration in pulmonary function, and 2 patients (3.6%) had Grade 3 pneumonitis. CONCLUSION Proton beam therapy was effective and well tolerated in medically inoperable patients with Stage I NSCLC.

[1]  G. Sibley.  Radiotherapy for patients with medically inoperable stage I nonsmall cell lung carcinoma , 1998, Cancer.

[2]  Daniel W. Miller,et al.  Hypofractionated proton beam radiotherapy for stage I lung cancer. , 2004, Chest.

[3]  R. Byhardt.  Baseline pulmonary function as a predictor for survival and decline in pulmonary function over time in patients undergoing stereotactic body radiotherapy for the treatment of stage I non–small-cell lung cancer , 2009 .

[4]  H. Kato,et al.  A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. , 2004, The New England journal of medicine.

[5]  K. Johansson,et al.  Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer--mature results for medically inoperable patients. , 2006, Lung cancer.

[6]  M. Melamed,et al.  The effect of surgical treatment on survival from early lung cancer. Implications for screening. , 1992, Chest.

[7]  Lech Papiez,et al.  Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. , 2005, International journal of radiation oncology, biology, physics.

[8]  Jacques Ferlay,et al.  Estimating the world cancer burden: Globocan 2000 , 2001, International journal of cancer.

[9]  Fletcher Cm.  The clinical diagnosis of pulmonary emphysema; an experimental study. , 1952 .

[10]  R. Sweeney,et al.  Photons or Protons: Precision Radiotherapy of Lung Cancer , 2007, Strahlentherapie und Onkologie.

[11]  T. Hashimoto,et al.  Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: preliminary results of a phase I/II clinical study. , 2007, International journal of radiation oncology, biology, physics.

[12]  Daniel W. Miller,et al.  Methodologies and tools for proton beam design for lung tumors. , 2001, International journal of radiation oncology, biology, physics.

[13]  I. Lax,et al.  The role of radiotherapy in treatment of stage I non-small cell lung cancer. , 2003, Lung cancer.

[14]  K. Nihei,et al.  High-dose proton beam therapy for Stage I non-small-cell lung cancer. , 2006, International journal of radiation oncology, biology, physics.

[15]  L V Rubinstein,et al.  Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. , 1995, The Annals of thoracic surgery.

[16]  Gregory C Sharp,et al.  Speed and amplitude of lung tumor motion precisely detected in four-dimensional setup and in real-time tumor-tracking radiotherapy. , 2006, International journal of radiation oncology, biology, physics.

[17]  K. Honma,et al.  Lymph node metastasis in small peripheral adenocarcinoma of the lung. , 1998, The Journal of thoracic and cardiovascular surgery.

[18]  L. Verhey,et al.  Relative biological effectiveness of modulated proton beams in various murine tissues. , 1984, International journal of radiation oncology, biology, physics.

[19]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[20]  Y. Tsunashima,et al.  Correlation between the respiratory waveform measured using a respiratory sensor and 3D tumor motion in gated radiotherapy. , 2004, International journal of radiation oncology, biology, physics.

[21]  E. Glatstein,et al.  Excessive Toxicity When Treating Central Tumors in a Phase II Study of Stereotactic Body Radiation Therapy for Medically Inoperable Early-Stage Lung Cancer , 2008 .

[22]  R K Ten Haken,et al.  Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. , 1999, Lung cancer.

[23]  S. Tyldesley,et al.  Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach. , 2001, International journal of radiation oncology, biology, physics.

[24]  T. Araki,et al.  Stereotactic hypofractionated high‐dose irradiation for stage I nonsmall cell lung carcinoma , 2004, Cancer.

[25]  R. Tsuchiya,et al.  Lymph node involvement, recurrence, and prognosis in resected small, peripheral, non-small-cell lung carcinomas: are these carcinomas candidates for video-assisted lobectomy? , 1996, The Journal of thoracic and cardiovascular surgery.

[26]  H. Satoh,et al.  Effect of heavy-ion radiotherapy on pulmonary function in stage I non-small cell lung cancer patients. , 2002, Chest.